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Background. Chronic allograft nephropathy (CAN) leads to
chronic allograft dysfunction and loss. Regular renal transplant
biopsies may be useful to find risk factors for CAN.
Methods. We carried out 688 protocol biopsies in 258 patients
at 6, 12, and 26 weeks after renal transplantation. Patients with
signs of CAN in the biopsy 3 (N = 70, CAN group), and those
without (N = 120, non-CAN group), were compared.
Results. Chronic tubulointerstitial changes increased from
biopsy 1 to 3 (5% vs. 37%, P < 0.0001). Fifty-six of 190 pa-
tients had acute rejection within 6 months (30%), 33 of which
were found in protocol biopsies (17%). On univariate analy-
sis, the CAN group had CAN more often at biopsy 2 than the
non-CAN group (23% vs. 4%, P < 0.0001), had a lower cal-
culated creatinine clearance at biopsy 1 and 2 (49.4 ± 25.8 vs.
57 ± 20.2 mL/min, P = 0.01; 47.3 ± 21.2 vs. 57.9 ± 19.5 mL/min,
P = 0.001, respectively), had a living donor less often than a
brain dead donor (7% vs. 18%, P = 0.045), had a longer cold
ischemia time (17.4 ± 7 vs. 14.9 ± 8.1 hours, P = 0.04), and had
arterionephrosclerosis more often (24% vs. 12%, P = 0.02). On
multivariate analysis, the differences in CAN at biopsy 2 (P =
0.001) and lower GFR at biopsy 2 (P = 0.002) were confirmed;
in addition, nephrocalcinosis (P = 0.006) and acute rejection
(P = 0.046) were found to occur more often.
Conclusion. Chronic tubulointerstitial changes develop early
after renal transplantation and are associated with reduced
kidney function. Risk factors for CAN are arterionephroscle-
rosis (donor-related), nephrocalcinosis (related to preexisting
hyperparathyroidism), a long cold-ischemia time (ischemia-
perfusion-related), and acute rejection. Renal functional
decline precedes morphologic changes of CAN, expressed as
tubular atrophy and interstitial fibrosis.
Chronic allograft nephropathy (CAN) leads to chronic
allograft dysfunction and is the most common cause of
allograft loss [1]. CAN is diagnosed clinically by a con-
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tinuous increase in serum creatinine, high blood pres-
sure, and proteinuria. Transplant biopsy at the time of
clinically advanced CAN shows mainly interstitial fibro-
sis and tubular atrophy as hallmarks of chronic trans-
plant injury; arterial intimal hyperplasia and fibrosis with
fibrointimal thickening (especially de novo), as well as
transplant glomerulopathy characterized most frequently
by glomerulosclerosis, can be found at a later point of time
([2–6]. The initiation of CAN, as well as the molecular and
cellular mechanisms and clinical risk factors, is not well
understood. Regular biopsies after renal transplantation
(protocol biopsies) may be useful to detect early changes
in the allograft and identifying risk factors for CAN.
The idea of protocol biopsies has existed since the
early days of renal transplantation ([7–12]. The purpose
of these biopsies was mainly analysis of the immediate
immunologic response of the graft and detection of acute
rejection. A predominant finding in these biopsies was
mononuclear interstitial cell infiltration, which was diffi-
cult to interpret. Because of the lack of therapeutic con-
sequences in most cases, protocol biopsies did not gain
importance as a regular clinical procedure.
Acute rejection became less important with modern
immunosuppression. Long-term graft survival and the
causes of CAN have become the central problem [1]. Im-
munologic as well as nonimmunologic risk factors are
presumed to induce CAN [2, 13]. Protocol biopsies again
received attention, no longer for the prevention of acute
rejection, but rather for the investigation and prevention
of CAN [6, 12, 14–23].
The Hannover Protocol Biopsy Program was started
in October 2000 with the intention of treating early acute
rejections and thereby preventing CAN [17], and iden-
tifying risk factors that predispose and promote chronic
allograft nephropathy.
METHODS
The protocol biopsy program at the Hannover Medical
School is part of the routine medical care following
transplantation, and has been approved by the local
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Ethics Committee. Protocol biopsies are carried out at
6, 12, and 26 weeks after renal transplantation as an out-
patient procedure. Patients are informed about the pro-
gram well before transplantation, and the reason for the
biopsies as a routine measure for the prevention of unde-
tected transplant damage is further discussed during the
patient visits to the transplant outpatient clinic following
transplantation. Written consent is obtained from each
patient at the patient visit before each biopsy (not before
transplantation). Thus, participation in the program is not
a requirement for transplantation.
The biopsies are done as an outpatient procedure
using an 18-gauge automated biopsy needle guided by
ultrasound. Two cores are obtained, 1 core for light mi-
croscopy, and 1 core is snap-frozen for further molecular
analysis. After the biopsy, patients have 4 hours of bed
rest with blood pressure and urine monitoring. The kid-
ney is examined by ultrasound before, immediately after,
and 4 hours after the biopsy procedure. In the case of a
biopsy-related complication, such as gross hematuria or
perirenal hematoma, or in the case of acute rejection, the
patients stay in hospital [24].
For induction of immunosuppressive therapy, 2 doses
of interleukin 2 antibody (basiliximab) on day 1 and 4 and
steroid boluses are given; maintenance immunosuppres-
sion consists of cyclosporine and steroids and, in cases of
high immunologic risk, as well as living related and unre-
lated transplantation, mycophenolate mofetil is given in
addition. When hemolytic uremic syndrome is the under-
lying kidney disease in the recipient, or in case of a donor
aged over 70 years, induction immunosuppression con-
sists of anti-thymoglobulin therapy and steroid boluses,
and maintenance immunosuppressive therapy consists of
mycophenolate mofetil and steroids. The cyclosporine
dose is adjusted to target trough levels (C12) of 180 ng/mL
during the first 3 months post-transplantation, and of
140 ng/mL thereafter; the target tacrolimus trough lev-
els are 10 ng/mL up to 3 months and 8 ng/mL thereafter,
respectively. In cases of acute rejection, including sub-
clinical rejection, we administered steroid pulses (biopsy
1 and 2) and switched from cyclosporine to tacrolimus
in the case of repeated rejection, or if rejection occurs
after more than 12 weeks’ (the time of biopsy 2) post-
transplantation. In exceptional cases, tacrolimus is given
as induction immunosuppression together with basilix-
imab, mycophenolate mofetil, and steroids in patients
with a very high immunologic risk. If borderline changes
are accompanied by an increase in creatinine (>15%),
they are treated as rejection; otherwise, they remain
untreated.
Histologic criteria
The local pathologist carried out a histologic evalua-
tion according to the updated Banff classification [3, 4].
That means that one pathologist recorded all biopsies (M.
Mengel), which avoids interobserver variability [25]. Fol-
lowing the Banff scheme, tubular atrophy is documented
even if only single tubules show signs of atrophy (base-
ment membrane thickening, flattened epithelial cells).
Interstitial fibrosis of the cortical area is estimated semi-
quantitatively. Only cases with greater than 5% of corti-
cal interstitial fibrosis and tubular atrophy are classified
as chronic allograft nephropathy (at least CAN grade I
according to the Banff classification). Thus, the basis of
the diagnosis of CAN is, according to the Banff classifica-
tion, the finding of tubular atrophy and interstitial fibro-
sis, since sampling error is less of a problem in sampling
tubules and interstitium, as long as sufficient cortical area
beyond the subcapsular zone is present [3, 4].
Tubular calcineurin inhibitor toxicity is defined as iso-
metric vacuolation of the cytoplasm of tubuloepithelial
cells with or without microcalcification, whereas vascu-
lar calcineurin inhibitor toxicity is defined as nodular
arteriolar hyalinosis of mostly afferent arterioles [26].
Arterionephroclerosis means fibrous intimal thicken-
ing suggestive more of hypertensive damage than of
chronic rejection (which would include intimal foam cells,
lymphocyte infiltration, or disruption of the elastica).
Nephrocalcinosis means focal (mild), multifocal (moder-
ate), or widespread (severe) detection of calcium deposits
in tubular epithelial cells or tubular lumina, respectively,
and rarely in the interstitial compartment.
All biopsies had sufficient cortical area for the evalua-
tion of interstitial fibrosis and tubular atrophy. Evaluat-
ing 1 tissue core, 46% of the biopsies (N = 319) showed
less than 7 glomeruli, and 11% (N = 78) contained no
arterial cross-section (glomeruli <7 and/or no arterial
cross-section; N = 359/688 = 48%). Thus, according to
the Banff recommendations on specimen adequacy, the
histologic evaluability was reduced for some criteria in
these cases [3]. However, when we compared the find-
ings in all biopsies to only those meeting the Banff crite-
ria of a minimum number of glomeruli and arteries, we
did not find any significant difference regarding the hall-
marks and possible risk factors of CAN (tubulointersti-
tial rejection, N = 52/688 vs. 32/359 biopsies; borderline
changes, N = 141/688 vs. 77/359; acute tubular changes,
N = 290/688 vs. 177/359; tubular changes suggestive of
calcineurin inhibitor toxicity, 91/688 vs. 62/359; arteriolar
changes suggestive of vascular calcineurin inhibitor toxic-
ity, 19/688 vs. 14/359; chronic tubulointerstitial changes of
>5%, 123/688 vs. 81/359; arterionephrosclerosis, 104/688
vs. 61/359; nephrocalcinosis, 74/688 vs. 33/359). The low
specimen adequacy of 1 core taken with an 18-gauge nee-
dle together with a low complication rate resulted in a
change to the use of a 16-gauge needle in October 2003.
Patient characteristics
One hundred ninety patients completed all 3 biopsies.
Following histologic analysis, 2 groups were established
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Table 1. Factors associated with chronic allograft nephropathy (CAN)
Statistical significance
CAN group Non-CAN group Univariate Multivariate
N = 70 N = 120 analysis analysis
Clinical criteria
Recipient age years 47.8 ± 13.5 48.7 ± 14.3 n.s. n.s.
Gender % males 66% 58% n.s. n.s.
Immunologic riska 14% 23% n.s. n.s.
HLA mismatches N 2.1 ± 1.6 2.4 ± 1.5 n.s. n.s.
Donor age years 47.8 ± 16 45.9 ± 17.2 n.s. n.s.
Living donor 7% 18% P = 0.045 n.s.
Cold ischemia time hours 17.4 ± 7 14.9 ± 8.1 P = 0.04 n.s.
Immediate graft function 63% 69% n.s. n.s.
Systolic blood pressure at biopsy 2 mm Hg 132 ± 10 131 ± 11 n.s. n.s.
Diastolic blood pressure at biopsy 2 mm Hg 80 ± 6 78 ± 7 n.s. n.s.
Pulse pressure at biopsy 2 mm Hg 52 ± 10 53 ± 11 n.s. n.s.
Antihypertensive drugs at biopsy 2 N 3 ± 1 2.9 ± 1.2 n.s. n.s.
Immunosuppression including CI at biopsy 2 94% 93% n.s. n.s.
Target trough level of CI at biopsy 1% 105 ± 53 101 ± 60 n.s. n.s.
Target trough level of CI at biopsy 2% 112 ± 49 102 ± 55 n.s. n.s.
Renal volume per kg body weight at biopsy 2 cm3/kg 2.2 ± 0.8 2.2 ± 0.7 n.s. n.s.
Body mass index at biopsy 2 24.4 ± 0.4 25.1 ± 0.3 n.s. n.s.
Resistance index at biopsy 1 0.73 ± 0.06 0.73 ± 0.08 n.s. n.s.
Resistance index at biopsy 2 0.72 ± 0.06 0.73 ± 0.08 n.s. n.s.
GFR at biopsy 1 mL/min 49 ± 26 57 ± 20 P = 0.03 n.s.
GFR at biopsy 2 mL/minb 47 ± 21 58 ± 19 P = 0.001 P = 0.002
OR = 1.03 (1.01–1.05)
Histologic criteria
CAN >5% at biopsy 1 9% 3% n.s. n.s.
CAN >5% at biopsy 2 23% 4% <0.0001 <0.001
OR = 6.1 (2.0–18.4)
Acute rejection at biopsy 1 7% 9% n.s. n.s.
Acute rejection at biopsy 2 10% 4% n.s. 0.046
OR = 3.7 (1.02–13.5)
Borderline changes at biopsy 1 29% 21% n.s. n.s.
Borderline changes at biopsy 2 23% 21% n.s. n.s.
Acute tubular changes at biopsy 1 40% 45% n.s. n.s.
Acute tubular changes at biopsy 2 41% 43% n.s. n.s.
Isometric vacuolation of tub. epith. cytoplasm at biopsy 1c 11% 13% n.s. n.s.
Isometric vacuolation of tub. epith. cytoplasm at biopsy 2c 14% 18% n.s. n.s.
Arteriolar hyalinosis at biopsy 1d 1% 3% n.s. n.s.
Arteriolar hyalinosis at biopsy 2d 3% 3% n.s. n.s.
Nephrocalcinosis at biopsy 1 10% 3% n.s. n.s.
Nephrocalcinosis at biopsy 2 14% 10% P = 0.06 P = 0.006
OR = 7.1 (1.8–28.8)
Arterionephrosclerosis at biopsy 1 21% 8% P = 0.02 n.s.
Arterionephrosclerosis at biopsy 2 20% 16% n.s. n.s.
CI, calcineurin inhibitor. Patients with chronic tubulointersitial changes of more than 5% in the third protocol biopsy 6 months after renal transplantation (N = 70;
CAN group) were compared to patients without these changes (N = 120; non-CAN group).
aImmunological risk defined as retransplant and/or panel reactive antibodies >10%.
bBonferroni adjustment for multiple comparisons was performed and the significance level for 38 separate comparisons was set at P < 0.001.
cSuggestive of tubular CI toxicity.
dSuggestive of vascular CI toxicity.
and compared: the first group had chronic tubulointersti-
tial changes of more than 5% in the third protocol biopsy
as a sign of chronic allograft nephropathy according to the
Banff scheme (at least CAN grade I; N = 70, CAN group);
the second group did not have these chronic findings in
the third biopsy (N = 120, non-CAN group). The 2 groups
were compared using bivariate and multivariate analy-
sis according to renal function, as well as possible well-
known risk factors for chronic allograft nephropathy.
Clinical parameters entered in the uni- and multivari-
ate analysis were: recipient age, gender, immunologic risk
(defined as prior transplantation and/or panel reactive
antibodies >10%), number of HLA mismatches, donor
age, living or brain dead donor, cold ischemia time, im-
mediate or delayed graft function, mean home systolic
and diastolic blood pressure, pulse pressure, number of
antihypertensive drugs, use of calcineurin inhibitor and
percentage of its target trough level reached, transplant
kidney volume per kg body weight (cm3/kg BW), body
mass index, resistance index, and calculated glomerular
filtration rate (GFR) (Table 1). Histologic parameters in-
cluded in the uni- and multivariate analysis were: signs of
CAN >5%, acute cellular rejection, borderline changes,
acute tubular damage, signs of tubular or vascular
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calcineurin inhibitor toxicity, nephrocalcinosis, and arte-
rionephrosclerosis (Table 1).
In order to compare the 2 groups, each patient was
given a score for clinical and histologic risk factors. His-
tologic risk factors were those mentioned above. Clinical
risk factors were: immunologic risk, more than 3 HLA
mismatches, donor age >65 years, cold ischemia time
>16 hours, delayed graft function, systolic blood pres-
sure of >140 and diastolic blood pressure of >90 mm
Hg, pulse pressure of >50 mm Hg, calcineurin inhibitor
target trough level >115%, transplant kidney volume of
<1.7 cm3 per kg body weight, resistance index of >0.79,
and calculated creatinine clearance of <45 mL/min at the
first protocol biopsy.
Serum creatinine, calculated creatinine clearance, re-
sistance index, and height and weight to determine the
body mass index were always measured on the day of the
renal transplant biopsy. Creatinine clearance as a mea-
sure of glomerular filtration rate (GFR) was calculated
by the Cockcroft-Gault formula [27]. Parathyroid hor-
mone (PTH), serum calcium, and serum phosphate were
measured at the time of biopsy 1 to compare patients
with nephrocalcinosis with those without. All data are ex-
pressed as mean ± SD unless stated otherwise. Patient-
related clinical data, laboratory findings, and histologic
findings were recorded in a specially designed database.
Statistics
The SPSS statistical package (Version 11.0.1, SPSS,
Inc., Chicago, IL, USA) was used for all statistical anal-
yses. Unpaired t tests or chi-square analysis were used
as appropriate to assess the differences between groups.
Odds ratios (chronic allograft nephropathy defined as
chronic tubulointerstitial findings >5%) for the primary
end point were calculated from two-by-two contingency
tables (Fisher exact test). For multivariate analysis, the ef-
fect of multiple parameters (see above) on the presence
of CAN 6 months after transplantation was analyzed in all
190 cases with stepwise forward logistic regression analy-
sis (variables with a P value of 0.1 or more were removed
from the analysis, and variables with a P value of 0.05 or
less were retained). Bonferroni adjustment for multiple
comparisons was performed.
RESULTS
Between October 2000 to March 2003, 299 patients at-
tended the transplant outpatient clinic after renal trans-
plantation. We performed 688 protocol biopsies in 258
of these 299 transplant recipients (biopsy 1, N = 221;
biopsy 2, N = 244; biopsy 3, N = 223). Seven percent
of patients had a medical contraindication to biopsy:
23 patients had a known coagulation disorder or were on
anticoagulant or antiplatelet treatment (warfarin, phen-
coumaron, clopidogrel, or ticlopidine), or had severe and
Table 2. Histologic findings in 688 protocol renal transplant biopsies
of 258 patients
258 patients 688 biopsies
N N
Acute tubulointerstitial rejection 46 (18%) 52 (8%)
Clinically silent 37 (14%) 39 (6%)
Acute vascular rejection 1 1
Subclinical humoral rejection 3 3
Borderline changes 104 (40%) 141 (21%)
With creatinine increase 13 (5%) 13 (2%)
Acute tubular changes 168 (65%) 290 (42%)
Isometric vacuolation of tubular
Epithelial cytoplasma 67 (26%) 91 (13%)
Arteriolar hyalinosisa 14 (5%) 19 (3%)
Chronic tubulointerstitial changes of >5% 88 (34%) 123 (18%)
Arterionephrosclerosis 75 (29%) 104 (15%)
Nephrocalcinosis 55 (21%) 74 (11%)
Polyoma virus nephropathy 4 (2%) 4 (<1%)
Recurrent glomerulonephritis 1 1
De novo glomerulonephritis 1 1
aSuggestive of tubular and vascular calcineurin inhibitor toxicity.
prolonged wound healing problems; in another 8 patients,
these problems lasted only temporarily, and they partic-
ipated partially in the program. Patients on aspirin were
included in the program. The rate of patient acceptance
of the protocol biopsy program was 94% (17 patients
refused to participate in the biopsy program; another
19 patients refused single biopsies). In 42 other patients,
biopsies could not be performed for various reasons (hos-
pitalization or patient on vacation, graft failure, patient
death). Biopsies 1 to 3 were completed in 190 patients. Of
these, 27 had at least 1 previous transplantation, 14 pa-
tients had combined pancreas-kidney transplantation,
and 28 patients had received the kidney from a living
donor.
One patient lost his graft because of repeated acute and
then chronic rejection after 4 months; 1 other patient with
mild chronic changes lost her graft because of additional
prerenal heart failure after 8 months. One patient died
after 6 months because of septicemia of unknown origin.
Histologic analysis
The histologic findings of 688 protocol biopsies in
258 patients are shown in Table 2. The histologic find-
ings relative to the time of biopsy in 190 patients who
completed all 3 biopsies are shown in Figure 1. Only the
results obtained in the 190 patients who completed all 3
biopsies are considered below.
Biopsy-proven acute rejection (including biopsies on
indication) was seen in 56/190 patients (30%) during the
first 6 months; rejection was found in protocol biopsies
in 33/190 patients (17%). Subclinical rejection (without
serum creatinine increase of >15% of baseline) was seen
in 27 patients (14%) (Table 2). Among protocol biopsies,
acute rejection was seen more often in biopsy 1 (8%)
than in biopsy 2 (6%) and biopsy 3 (5%) (Fig. 1). Vas-
cular rejection was seen only once in a protocol biopsy,
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Fig. 1. Histopathologic findings according to the time of biopsy after renal transplantation (N = 190).
and otherwise in 5 biopsies on indication (6/190 patients,
3%). Vascular rejection was always accompanied by an
increase in serum creatinine, and was followed by signs
of CAN in the third biopsy in 5 of 6 cases.
CAN (at least grade I according to the Banff classifica-
tion) was found in 5% of the first biopsies, and increased
significantly from the second biopsy (11%) to the third
biopsy (N = 70, 37%; P < 0.0001; Figs. 1 and 2). In 8
cases, chronic tubulointerstitial changes of a mild degree
as seen in biopsy 1 or 2 were not found in biopsy 3 (4%);
in 1 further case, the changes regressed. In all other cases,
chronic tubulointerstitial changes progressed.
Nephrocalcinosis increased significantly from the first
biopsy (6%) to the second biopsy (12%; P < 0.05); in
the third biopsy, it was even 18%. Calcium deposits were
localized mostly in tubular epithelial cells or in the tubu-
lar lumen, and were rarely interstitial (Fig. 3). Patients
with nephrocalcinosis (N = 52) had a significantly higher
PTH at biopsy 1 than those without (N = 138) (387 ±
267 vs. 133 ± 119 pg/mL; P < 0.0001). Serum calcium
and phosphate were not significantly different (2.56 ±
0.16 vs. 2.49 ± 1.71 mmol/L, n.s.; 0.8 ± 0.21 vs. 0.87 ±
0.28 mmol/L, n.s., respectively). Twenty of 190 patients
(11%) needed parathyroidectomy during the 18 months
post-transplant; all of them had nephrocalcinosis. Thirty-
seven patients (20%) had had parathyroidectomy before
transplantation; only 5 of these had nephrocalcinosis.
Patients with arterionephrosclerosis in the transplant
(N = 62) had a significantly older donor than patients
without (N = 128; 55 ± 11.7 vs. 47.7 ± 17.4 years; P <
0.0001).
Serum creatinine and chronic tubulointerstitial dam-
age as estimated by the pathologist semiquantitatively
showed a statistically significant correlation in biopsy 3
(correlation coefficient R= 0.274, intercept a = 148 ± 6,
slope b = 3.30 ± 0.84, P = 0.0001).
Risk factors for chronic allograft nephropathy
Among the 190 patients who completed biopsies 1 to 3,
the patient group with chronic tubulointerstitial changes
(>5%) in biopsy 3 (N = 70, defined as CAN group) was
compared with the other patients without these changes
(N = 120, non-CAN group; Table 1). On univariate anal-
ysis, the CAN group already showed CAN significantly
more often at biopsy 2; they had a significantly lower cal-
culated GFR at the time of biopsy 1 and 2 beginning at
6 weeks post-transplantation than the non-CAN group;
they had a significantly longer cold ischemia time, had
a living rather than a brain dead donor significantly less
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Fig. 2. Typical example of a patient with protocol biopsies. (A) First
biopsy after 6 weeks (subclinical tubulointerstitial rejection); (B) second
biopsy after 12 weeks (borderline changes); (C) third biopsy after 26
weeks (tubular atrophy and interstitial fibrosis of 30%).
Fig. 3. Nephrocalcinosis showing intratubular calcium deposits.
often, and had arterionephrosclerosis at biopsy 1 signif-
icantly more often than the non-CAN group (Table 1).
On multivariate analysis, significant differences were con-
firmed for CAN at biopsy 2, as well as for a lower GFR at
biopsy 2; additionally, nephrocalcinosis at biopsy 1, and
acute rejection at biopsy 2, occurred significantly more
often (Table 1). Possible other clinical factors influencing
the development of chronic allograft nephropathy and
other histologic features, as listed in Table 1, did not dif-
fer significantly between the 2 groups on univariate and
multivariate statistical analysis.
Performing a patient score of histologic and clinical
risk factors, the CAN group had a significantly higher
score than the non-CAN group (CAN group vs. non-CAN
group 5.27 ± 2.4 vs. 4.41 ± 2.04, P = 0.01). However, when
the histologic and clinical risk factors were separated, the
only significant difference between the groups was in the
patient score for histologic risk factors (2.27 ± 2.71 vs.
1.53 ± 0.95, P = 0.01).
DISCUSSION
Protocol biopsies in the early course after renal trans-
plantation revealed that chronic allograft nephropathy
starts early. In our investigation, 37% of transplants
showed chronic tubulointerstitial changes affecting more
than 5% of the cortical area after only 6 months (CAN at
least grade I; Figs. 1 and 2). Chronic glomerular changes
such as double contours in capillary loops and glomeru-
lulosclerosis, as well as chronic vascular changes such as
fibrointimal thickening, especially de novo, were rarely
seen in the histology of our patients; these are late find-
ings in allograft nephropathy [6]. Others have also found
chronic allograft nephropathy in 25% to 35% of cases af-
ter 3 months [6, 12, 14, 15, 22]. However, there are patients
described in the literature who did not develop chronic
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allograft nephropathy up to 2 and 5 years, respectively,
after transplantation; these patients had HLA-identical
grafts from living donors, and had a short cold ischemia
time because of living donation [5, 12].
Renal function (C&G GFR) was significantly lower
in patients with chronic tubulointerstitial changes after
6 months (the CAN group). Low GFR at the time of pro-
tocol biopsy 2 was the strongest risk factor for chronic
tubulointerstitial changes in biopsy 3 (Table 1). Surpris-
ingly, however, the calculated GFR was already lower in
the CAN group at the time of the first biopsy after 6 weeks,
almost to the same extent as at the time of the third biopsy,
although chronic changes in histology were seen in only
9% of the patients in that group at biopsy 1 (30% at
biopsy 2, 37% at biopsy 3). The finding of a functional de-
cline prior to morphologic CAN changes was confirmed
by another protocol biopsy group [abstract 436; Cosio
et al, Mayo Clinic, ATC May 15–19, 2004; and per-
sonal communication]. That could mean that functional
changes from any cause precede histologic changes and
might be partially reversible at that time, if pathophysio-
logic understanding, as well as intervention in the fibrotic
mechanisms, were possible. However, donor-related ar-
terionephrosclerosis, more often found in the CAN group
at biopsy 1 (but not at biopsy 2 and 3, Table 1), could play
a role in functional decline as well [28].
From the immunologic point of view, a further risk fac-
tor for chronic tubulointerstitial changes was acute rejec-
tion at biopsy 2; from the nonimmunologic point of view,
the risk factors were nephrocalcinosis, arterionephroscle-
rosis, cold ischemia time, and nonliving donation
(Table 1). In general, the risk factor score representing
chronic histologic changes was significantly higher in the
CAN than in the non-CAN group, while that for clinical
risk factors was not.
Nephrocalcinosis increased significantly from biopsy 1
to 3 (Fig. 1), and was associated with CAN in biopsy 3
(Table 1). Patients with nephrocalcinosis had a higher
PTH than those without. The clear clinical conclusion
of this finding is to avoid severe hyperparathyroidism at
renal transplantation, which means to transplant the pa-
tients earlier, or to control hyperparathyroidism either
by medication or operation before transplantation. All
patients who needed parathyroidectomy after transplan-
tation exhibited nephrocalcinosis and, thus, had a signif-
icant risk factor for CAN.
Donor age is usually considered to be a risk factor
for chronic allograft nephropathy ([12, 18, 20, 29, 30].
Donor age was higher in the CAN group, but this did
not reach statistical significance (Table 1). However, ar-
terionephrosclerosis occurred more often in the CAN
group, and donors of patients with arterionephrosclero-
sis were significantly older than donors of patients with-
out. Thus, donor conditions, especially with preexisting
arterionephrosclerosis, play a significant role in chronic
allograft nephropathy, which is confirmed in our investi-
gation [28]. Preexisting lesions on histology would have
been even more discernible with implantation biopsies
[28]; they were not done in this study because of avail-
ability (biopsies at implantation tend to cause bleeding
complications, and are not done randomly at our center).
The early biopsy 1 after 6 weeks is intended to replace
the implantation biopsy. Cold ischemia time as a deter-
minant of ischemia reperfusion injury is often blamed as
a risk factor for chronic allograft nephropathy, and was
confirmed in this investigation [22, 31, 32].
In the literature, acute rejection is usually considered a
risk factor for chronic allograft nephropathy [1, 12, 17, 18,
33, 34]. This is true especially for vascular rejection [6, 22,
35], late rejection [22, 34], and rejection with persistent
functional impairment [36, 37]. All clinically silent sub-
clinical rejections observed in our protocol biopsy pro-
gram were acute tubulointerstitial rejections; among the
other rejection episodes observed during the 6 months
post-transplantation, vascular rejection was rare (6 of 56
patients with rejection, 11%). Despite this, acute rejec-
tion was a risk factor for chronic allograft nephropathy
(Table 1). However, we cannot conclude from our study
that preemptive treatment of all rejection episodes, as
carried out in our program, reduces the risk of chronic
allograft nephropathy, since we treated them all. It would
have been difficult to justify randomisation for the treat-
ment of acute rejection.
Considered overall, chronic tubulointerstitial changes
in the sense of chronic allograft nephropathy started early
after renal transplantation (within months), and corre-
lated with renal function. It is noteworthy that a probably
purely functional decline in GFR seems to precede mor-
phologic changes of CAN, which argues for the possibility
of timely therapeutic intervention. A possible pathome-
chanism for this phenomenon might be related to the ex-
tracellular matrix turnover in allografts, as shown recently
for tissue transglutaminase, which may be seen before
morphologic changes as the “switch” between inflam-
mation (reversible) and renal scarring (irreversible) [38,
39]. Key molecules in fibrosis induction and renal scar-
ring might provide submorphologic diagnostic tools, and
are currently under investigation in our protocol biopsy
program.
Risk factors for chronic allograft nephropathy were
donor-related (represented by early arterionephroscle-
rosis), related to preexisting hyperparathyroidism (rep-
resented by nephrocalcinosis), ischemia-reperfusion–
related (represented by cold ischemia time and the
advantage of living donation), and of immunologic ori-
gin (represented by early rejection). However, the statis-
tical significance of these risk factors was not very strong,
and some of the CAN patients had a very low risk factor
score for CAN. On this clinical basis, further molecular,
morphologic, and genetic research programs will have to
348 Schwarz et al: CAN after transplantation
elucidate the large differences in the degree of chronic al-
lograft nephropathy between individual renal transplant
recipients.
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